Meridian Bioscience Awarded New Agreement With Premier Healthcare Alliance For Molecular Diagnostic Tests And Instruments For C. Difficile And Group B Streptococcus

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has signed a new group purchasing agreement with the Premier healthcare alliance to offer illumigene ® C. difficile and illumigene Group B Streptococcus to its members at specially negotiated pricing. Premier serves more than 2,500 U.S. hospitals and 81,000-plus other healthcare sites. This agreement allows Premier alliance facilities to implement rapid, sensitive molecular tests for C. difficile and Group B Streptococcus without individual negotiations.

Premier’s mission is “to improve the health of communities” and using the power of collaboration to lead the transformation to high-quality, cost-effective care aligns with Meridian’s promise to provide a new standard for patient care with our innovative diagnostic testing solutions. Meridian is privileged to be awarded this agreement with Premier and Premier members to assist their efforts to improve quality of patient care and reduce healthcare costs.

The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology. The test procedure is remarkably simple, highly sensitive, and yields results in less than one hour. It requires no expensive capital equipment. The test relies upon a simple procedure that includes heat treatment, amplification and detection. The entire amplification is isothermal and results are read on the illumipro-10™ instrument. All reagents and disposables are contained in the test kit and can be stored at room temperature. Meridian believes that the “point-of-care” simplicity of this technology, along with its cost efficiency, make illumigene ideal for helping in early diagnosis and proper management of preventable and treatable diseases, especially in those instances where there is a low level of the biological target.

Richard L. Eberly, Chief Commercial Officer, commented, “This is an exciting opportunity for Meridian to accelerate illumigene placements to Premier members. We are privileged to collaborate with the Premier healthcare alliance to assist Premier members in their efforts to improve the quality of patient care and drive costs out of their facilities.”

About the Premier Healthcare Alliance, Malcolm Baldrige National Quality Award recipient

Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 81,000-plus other healthcare sites using the power of collaboration to lead the transformation to high-quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington. Stay connected with Premier on Facebook, Twitter and YouTube.


If you liked this article you might like

3 Undiscovered, Undervalued Health Care Stocks Poised to Outperform the Sector in 2016

Insider Trading Alert - VIVO, CCG And PDCE Traded By Insiders

Meridian Bioscience (VIVO) Weak On High Volume

Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom

Meridian Bioscience (VIVO) Upgraded From Hold to Buy